LAG3 and neoplasm: Second, although our subcutaneous tumor model showed that LAG3 knockdown promoted tumor growth, the mouse immune system and tumor microenvironment differed significantly from that of humans, and these interspecies differences may require further validation of the clinical relevance of LAG3 through patient‐derived xenograft (PDX) models or clinical cohorts.